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Abstract: The relationship between intraocular pressure (IOP) and glaucoma is complex and not fully understood. We 
question the validity of several claims relating to the IOP-glaucoma relationship: (1) that 12 mm Hg is an important target 
in IOP control; (2) that IOP variability is an important risk factor for glaucoma progression; and (3) that every millimeter 
of mercury of IOP lowering reduces the risk of glaucoma progression by some specific percentage amount. Further, IOP 
is generally accepted to be an important – if not most important – risk factor  for glaucoma development and progression. 
Using measures of treatment effect – absolute risk reduction, relative risk, and relative risk reduction – we compare the 
strength of IOP as a risk factor to the strength of a cardiac risk factor in cardiovascular disease. 
INTRODUCTION 
  That intraocular pressure (IOP) is intricately linked with 
primary open-angle glaucoma (POAG) is well established. 
Yet, specific details of this relationship have been the subject 
of considerable debate over many years. The question of 
“does IOP measure up” can be explored in several ways. One 
approach considers our gaps in knowledge of IOP, due in 
part to our inability to measure true IOP continuously. The 
accuracy of even snapshot IOP measurements at various 
times of the day is limited by factors such as corneal 
thickness and elasticity. Advances in our ability to accurately 
measure IOP both in the office as well as over 24 hours will 
undoubtedly improve our understanding of the IOP-POAG 
relationship in future years. For now, a number of issues 
relating to IOP have been subject to varying interpretations. 
Several of these interpretations have been accepted by some 
as dogma. One of us (mrw) in an article titled, “The Myth of 
21 mm Hg” questioned past IOP dogma and cautioned 
against drawing definitive conclusions from insufficient data 
[1]. We explore several issues of IOP for which conclusions 
have been made which we believe should be examined 
further. 
  Another approach in addressing this topic is to compare 
how IOP as a risk factor for POAG compares in its 
predictive ability with risk factors for other diseases for 
which we have robust data. Cardiovascular disease is one 
such disease for which there exists considerable data. 
Recently completed glaucoma clinical trials provide data to 
calculate treatment effect of IOP reduction which can be 
compared to treatment effect of a known risk factor in 
cardiovascular disease. We use both approaches to address 
the question of “does it measure up”. 
IOP AND THE KNOWLEDGE GAP 
  There is much that we know about IOP. Virtually all 
cross-sectional, population-based studies of POAG have   
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demonstrated that the prevalence of POAG increases with 
increasing IOP [2-6]. The logical inference from this data 
was that IOP is a risk factor for the development of 
glaucomatous optic nerve damage. Further, clinical 
experience strongly supported the inference that lowering 
IOP slows the progression of glaucomatous optic nerve 
damage. Both of these inferences have recently been proven 
through several large, prospective trials of subjects with 
elevated IOP who were either treated medically or observed 
without treatment [7, 8].
 
  `We also know that IOP fluctuates over the diurnal and 
nocturnal periods and that this fluctuation is influenced by 
factors such as body position [9, 10]. The IOP of a patient 
lying down can be at least 3 to 4 mm Hg higher than that of a 
patient who is sitting. Thus, many patients have higher IOPs 
at night when they are sleeping than during the day when 
they are sitting or standing. 
  Yet, the significance of this information, particularly as it 
relates to consequences for the individual patient, is not 
clearly understood. In part, this is due to a lack of tools to 
continuously monitor true IOP over an entire 24-hour period. 
Another problem is that we do not know which attribute of 
IOP—mean IOP, peak IOP, fluctuation or variability of 
IOP—is most important as a risk factor for glaucomatous 
progression. Some argue that keeping a patient’s average 
IOP as low as possible should be the primary treatment goal; 
some others believe it is most important to always stay 
below an arbitrary IOP target; still others believe that 
minimizing IOP fluctuations over 24 hours and between 
visits is most important. 
  It is clear that while the IOP-glaucoma relationship has 
become better understood over the past several decades, 
there remains much that is subject to debate. And while a 
number of myths relating to IOP have been debunked, others 
have taken its place. One such myth is that 12 mm Hg is an 
important target in IOP control, and has replaced 21 mm Hg 
as the critical target goal in glaucoma care. 
  This myth has been supported by a post-hoc analysis 
examining data from the Advanced Glaucoma Intervention 
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relative merits of two sequences of interventions in 
glaucoma patients whose IOP was uncontrolled despite 
receiving maximum medical therapy [11]. Patients were 
assigned,  via  randomization, to undergo argon laser 
trabeculoplasty (ALT) or trabeculectomy first, followed by 
the alternative procedure if the first failed to sufficiently 
reduce the IOP, and then by a second trabeculectomy if both 
procedures failed. 
  The AGIS investigators, in addition to studying the initial 
question, performed several post-hoc analyses to address 
questions that the study was not initially designed to answer. 
In one such analysis, the investigators pooled all patients 
from both groups and examined the relationship between 
IOP and glaucoma progression over time. Of the four 
subgroups of patients with varying proportions of IOP   
measurements below 18 mm Hg, the group which showed no 
net progression on visual fields had IOPs of lower than 18 
mm Hg on all visits (Fig. 1). This group also had an average 
IOP of 12.3 mm Hg. The other groups, which had IOPs below 
18 mm Hg less frequently, had higher rates of progression, 
creating what appeared to be a dose response curve for IOP 
as a cause of glaucoma progression. 
  However, one cannot make the assumption that patients 
in these four groups were comparable with regard to baseline 
characteristics in the same manner as would have occurred 
with randomization. While this post-hoc analysis did reveal 
that the subgroup of patients with IOPs lower than 18 mm 
Hg on all visits had an average IOP of 12.3 mm Hg and, on 
average, showed no visual field progression, this does not by 
any means suggest that all such patients were stable. Given 
the variability in visual field testing, all one can conclude is 
that this group demonstrated no progression on average. 
Some may have shown worsening on visual field scores 
while others improved. Most importantly, there is no 
convincing evidence from this, or any other analysis, that 
glaucoma progression can be completely halted in all 
patients if one achieves an IOP of 12 mm Hg or any other 
arbitrary target. 
  A later analysis from AGIS resulted in another potential 
myth, one pertaining to the importance of IOP variability 
between visits as a risk factor for glaucoma progression [12] 
(Fig. 2). According to these data, the risk of visual field loss 
was greater for patients whose IOP varied to a larger degree 
from the mean relative to those with steadier IOPs. However, 
AGIS was not designed to address this issue. Since treatment 
was advanced when IOP was higher, it is reasonable to 
expect greater IOP variability with more interventions as a 
result of more progressive disease. A subsequent analysis 
from the Early Manifest Glaucoma Trial (EMGT) did not 
include postprogression IOP values, which would be biased 
toward larger fluctuations because of more intensive therapy 
[13]. This study showed that the mean rather than variability 
of IOP correlated best with progression. A repeat analysis 
from AGIS was performed that adjusted for the flaw in the 
initial analysis of allowing for the use of both pre and post 
intervention data from multiple interventions [14]. In this 
reanalysis, IOP variation was an important independent risk 
factor for progression, but only in the subset of patients who 
had low IOPs during the course of the study. Such 
conflicting data underscores the fact that there is still much 
to learn about the relationship between IOP variability and 
glaucoma progression. 
  A third potential myth is the claim that every millimeter 
of mercury of IOP lowering reduces the risk of glaucoma 
progression by some specific percentage amount. This 
assertion is supported by data from the Early Manifest 
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Glaucoma Trial (EMGT)
 which showed an estimated 11% 
higher risk of progression for every mm Hg higher IOP [8]. 
In the EMGT, patients were randomly assigned to treatment 
or no treatment for newly diagnosed glaucoma. The treated 
group experienced progression less frequently than the 
untreated group, but both groups were found to have 
significant rates of progression, presumably related to less 
than optimal IOP lowering. While there was a mean IOP 
lowering of approximately 25% in this study, there was no 
minimum required and treatment did not have to be 
advanced, for example, if IOP remained unchanged with 
therapy. In contrast to the EMGT findings, the Collaborative 
Initial Glaucoma Treatment Study (CIGTS) found that in 
patients with newly diagnosed glaucoma who were randomly 
assigned either to undergo surgery or to receive medical 
treatment first, the surgery-first group experienced a greater 
IOP reduction, by an average of 2 to 3 mm Hg, than the 
medicine-first group throughout the 5-year course of the 
study [15]. But after 5 years, no difference in visual field 
preservation was detected between the medicine and surgery 
first groups. 
  A plausible conclusion from these disparate results is that 
one sees diminishing returns with IOP lowering such that 
every millimeter of mercury of IOP lowering may not have 
equivalent weight across the IOP spectrum. In CIGTS, the 
average IOP reduction was more than 35% in both groups, a 
substantially greater amount than that found in EMGT. This 
suggests that the first few millimeters of mercury of 
reduction may result in a greater decrease in risk, perhaps 
10% per millimeter of mercury, as suggested by EMGT, but 
 
Fig. (2). IOP variability and visual field progression from advanced glaucoma intervention study. 
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once IOP has been lowered substantially, as in CIGTS, 
additional IOP lowering may be associated with less risk 
reduction. 
IOP AS A RISK FACTOR 
  Notwithstanding the above examples, which highlight a 
number of unanswered questions regarding the relationship 
between IOP and POAG, IOP is considered to be an 
important risk factor for glaucoma. Because it is the only 
known risk factor amenable to modification, it can be argued 
that it is the most important risk factor for POAG. Recently, 
the epidemiology of POAG has been compared to the 
epidemiology of cardiovascular disease [16]. In this context, 
risk calculators using IOP as well as other risk factors have 
been developed in an effort to emulate the risk calculations 
used with cardiac risk factors for predicting a cardiac event. 
Implicit in such risk assessments has been a comparison of 
the strength of IOP as a risk factor relative to the strength of 
some of the modifiable cardiac risk factors. 
  Such a comparison must take into account the nature of 
the disease itself. As shown in Fig. (3), glaucoma comprises 
a continuum of disease states from undetectable disease, 
characterized by ganglion cell death and axonal loss, to 
asymptomatic disease in which optic nerve changes and 
early to mild visual field defects are noted, to symptomatic 
disease in which visual field loss is severe or total [17]. The 
time frame from the beginning of the continuum to the end is 
measured—in the vast majority of cases— in decades. Thus, 
all of the major glaucoma clinical trials that have examined 
the IOP-POAG relationship have necessarily focused on 
only a small segment of this continuum. The outcome of 
importance to the patient with POAG is symptomatic 
disease, particularly blindness, which is at the end of the 
continuum. Risk factors are typically associated with the 
beginning stages of the disease. Because of the long time 
frame and the lack of a study spanning the entire spectrum of 
POAG, the link between IOP as a risk factor and blindness is 
tenuous. In comparison, cardiac risk factors typically predict 
a single memorable event, an event that often results in 
death. The link between these risk factors and the cardiac 
event is extremely strong. 
 
Fig. (4). Different ways of expressing treatment effect. 
  One way to assess the strength of a risk factor is to 
measure the effectiveness of treating to modify the risk 
factor. As noted in Fig. (4), treatment effect can be expressed 
in different ways including Absolute Risk Reduction (ARR), 
Relative Risk (RR), and Relative Risk Reduction (RRR) [18]. 
These measures of treatment effect can be calculated using 
the three year risk of a cardiovascular event with and without 
statin therapy (Fig. 5) [19]. The results can be compared to 
the five year risk of developing glaucoma with and without 
treatment in the Ocular Hypertension Treatment Study (Fig. 
6) [7], and the six year risk of glaucoma progression with 
and without therapy in the Early Manifest Glaucoma Trial 
(Fig. 7) [8]. A direct comparison of the results is difficult 
because of the differing time lines used. However, it is clear 
that the greatest reduction in risk is with the statins in 
cardiovascular disease, followed closely by treatment of 
elevated IOP in early glaucoma. The risk reduction achieved 
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with treatment of elevated IOP in ocular hypertension is 
sizable but is not to the same extent as in cardiovascular 
disease and early glaucoma. 
CONCLUSION 
  Since 1622, when Rikchard Banister first noticed a 
connection between hard eyeballs and blindness, IOP and 
primary open-angle glaucoma has been inexorably linked. 
Yet, much still remains to be learned about the IOP-POAG 
relationship. Our knowledge would be advanced by an 
ability to more accurately and continuously measure IOP. 
  Over the past several years, there has been a growing 
interest in glaucoma risk assessment. Without dispute, IOP is 
a strong risk factor for glaucoma development and glaucoma 
progression. However, it is the only modifiable risk factor 
identified thus far. The value of glaucoma risk assessment 
would be greater if more modifiable risk factors were to be 
identified. Similarly, the value would be greater if a stronger 
connection between IOP and blindness could be established. 
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